vs
AMERICAN PUBLIC EDUCATION INC（APEI）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是AMERICAN PUBLIC EDUCATION INC的1.3倍（$207.3M vs $158.3M），AMERICAN PUBLIC EDUCATION INC净利率更高（8.0% vs -62.0%，领先70.0%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -3.5%），AMERICAN PUBLIC EDUCATION INC自由现金流更多（$-15.6M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 1.3%）
美国公共教育公司（股票代码APEI）旗下控股教育服务企业Strategic Education Inc，运营着卡佩拉大学、斯特雷耶大学两所营利性在线大学，还拥有DevMountain、Hackbright Academy、Sophia Learning等非学历教育项目，主营面向在职人群的成人教育服务。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
APEI vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $158.3M | $207.3M |
| 净利润 | $12.6M | $-128.6M |
| 毛利率 | 56.4% | — |
| 营业利润率 | 12.0% | -54.7% |
| 净利率 | 8.0% | -62.0% |
| 营收同比 | -3.5% | 25.9% |
| 净利润同比 | -2.7% | 3.5% |
| 每股收益（稀释后） | $0.67 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $158.3M | $207.3M | ||
| Q3 25 | $163.2M | $159.9M | ||
| Q2 25 | $162.8M | $166.5M | ||
| Q1 25 | $164.6M | $139.3M | ||
| Q4 24 | $164.1M | $164.6M | ||
| Q3 24 | $153.1M | $139.5M | ||
| Q2 24 | $152.9M | $147.0M | ||
| Q1 24 | $154.4M | $108.8M |
| Q4 25 | $12.6M | $-128.6M | ||
| Q3 25 | $5.6M | $-180.4M | ||
| Q2 25 | $4.5M | $-115.0M | ||
| Q1 25 | $8.9M | $-151.1M | ||
| Q4 24 | $13.0M | $-133.2M | ||
| Q3 24 | $2.3M | $-133.5M | ||
| Q2 24 | $371.0K | $-131.6M | ||
| Q1 24 | $516.0K | $-170.7M |
| Q4 25 | 56.4% | — | ||
| Q3 25 | 54.2% | — | ||
| Q2 25 | 51.8% | — | ||
| Q1 25 | 54.5% | — | ||
| Q4 24 | 56.3% | — | ||
| Q3 24 | 50.8% | — | ||
| Q2 24 | 50.2% | — | ||
| Q1 24 | 53.1% | — |
| Q4 25 | 12.0% | -54.7% | ||
| Q3 25 | 5.9% | -106.9% | ||
| Q2 25 | 4.3% | -64.8% | ||
| Q1 25 | 7.4% | -102.6% | ||
| Q4 24 | 13.1% | -74.3% | ||
| Q3 24 | 2.7% | -94.6% | ||
| Q2 24 | 1.5% | -79.1% | ||
| Q1 24 | 3.4% | -151.9% |
| Q4 25 | 8.0% | -62.0% | ||
| Q3 25 | 3.4% | -112.8% | ||
| Q2 25 | 2.8% | -69.0% | ||
| Q1 25 | 5.4% | -108.5% | ||
| Q4 24 | 7.9% | -80.9% | ||
| Q3 24 | 1.5% | -95.7% | ||
| Q2 24 | 0.2% | -89.5% | ||
| Q1 24 | 0.3% | -156.8% |
| Q4 25 | $0.67 | $-1.28 | ||
| Q3 25 | $0.30 | $-1.81 | ||
| Q2 25 | $-0.02 | $-1.17 | ||
| Q1 25 | $0.41 | $-1.57 | ||
| Q4 24 | $0.63 | $-1.34 | ||
| Q3 24 | $0.04 | $-1.40 | ||
| Q2 24 | $-0.06 | $-1.52 | ||
| Q1 24 | $-0.06 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $174.1M | $421.0M |
| 总债务越低越好 | $94.7M | — |
| 股东权益账面价值 | $294.8M | $-80.0M |
| 总资产 | $521.4M | $1.5B |
| 负债/权益比越低杠杆越低 | 0.32× | — |
8季度趋势，按日历期对齐
| Q4 25 | $174.1M | $421.0M | ||
| Q3 25 | $191.3M | $202.5M | ||
| Q2 25 | $174.9M | $176.3M | ||
| Q1 25 | $161.6M | $127.1M | ||
| Q4 24 | $131.9M | $174.0M | ||
| Q3 24 | $135.4M | $150.6M | ||
| Q2 24 | $129.8M | $480.7M | ||
| Q1 24 | $125.3M | $112.3M |
| Q4 25 | $94.7M | — | ||
| Q3 25 | $94.4M | — | ||
| Q2 25 | $94.1M | — | ||
| Q1 25 | $93.7M | — | ||
| Q4 24 | $93.4M | — | ||
| Q3 24 | $93.1M | — | ||
| Q2 24 | $92.8M | — | ||
| Q1 24 | $95.0M | — |
| Q4 25 | $294.8M | $-80.0M | ||
| Q3 25 | $279.3M | $9.2M | ||
| Q2 25 | $272.2M | $151.3M | ||
| Q1 25 | $310.0M | $144.2M | ||
| Q4 24 | $303.9M | $255.0M | ||
| Q3 24 | $290.4M | $346.8M | ||
| Q2 24 | $288.7M | $432.4M | ||
| Q1 24 | $288.5M | $140.3M |
| Q4 25 | $521.4M | $1.5B | ||
| Q3 25 | $525.3M | $1.2B | ||
| Q2 25 | $537.4M | $1.3B | ||
| Q1 25 | $578.7M | $1.3B | ||
| Q4 24 | $570.1M | $1.5B | ||
| Q3 24 | $569.6M | $1.5B | ||
| Q2 24 | $560.7M | $1.6B | ||
| Q1 24 | $559.0M | $1.3B |
| Q4 25 | 0.32× | — | ||
| Q3 25 | 0.34× | — | ||
| Q2 25 | 0.35× | — | ||
| Q1 25 | 0.30× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.32× | — | ||
| Q2 24 | 0.32× | — | ||
| Q1 24 | 0.33× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-11.6M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $-15.6M | $-100.8M |
| 自由现金流率自由现金流/营收 | -9.9% | -48.6% |
| 资本支出强度资本支出/营收 | 2.6% | 0.5% |
| 现金转化率经营现金流/净利润 | -0.92× | — |
| 过去12个月自由现金流最近4个季度 | $46.1M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $-11.6M | $-99.8M | ||
| Q3 25 | $21.7M | $-91.4M | ||
| Q2 25 | $14.8M | $-108.3M | ||
| Q1 25 | $37.0M | $-166.5M | ||
| Q4 24 | $1.6M | $-79.3M | ||
| Q3 24 | $14.1M | $-67.0M | ||
| Q2 24 | $12.5M | $-77.0M | ||
| Q1 24 | $20.7M | $-190.7M |
| Q4 25 | $-15.6M | $-100.8M | ||
| Q3 25 | $17.5M | $-92.7M | ||
| Q2 25 | $11.1M | $-110.7M | ||
| Q1 25 | $33.1M | $-167.8M | ||
| Q4 24 | $-1.8M | $-79.5M | ||
| Q3 24 | $7.8M | $-68.6M | ||
| Q2 24 | $7.3M | $-79.0M | ||
| Q1 24 | $14.5M | $-193.9M |
| Q4 25 | -9.9% | -48.6% | ||
| Q3 25 | 10.7% | -58.0% | ||
| Q2 25 | 6.8% | -66.5% | ||
| Q1 25 | 20.1% | -120.5% | ||
| Q4 24 | -1.1% | -48.3% | ||
| Q3 24 | 5.1% | -49.2% | ||
| Q2 24 | 4.7% | -53.7% | ||
| Q1 24 | 9.4% | -178.2% |
| Q4 25 | 2.6% | 0.5% | ||
| Q3 25 | 2.6% | 0.8% | ||
| Q2 25 | 2.3% | 1.5% | ||
| Q1 25 | 2.4% | 1.0% | ||
| Q4 24 | 2.0% | 0.1% | ||
| Q3 24 | 4.1% | 1.2% | ||
| Q2 24 | 3.4% | 1.4% | ||
| Q1 24 | 4.0% | 3.0% |
| Q4 25 | -0.92× | — | ||
| Q3 25 | 3.90× | — | ||
| Q2 25 | 3.29× | — | ||
| Q1 25 | 4.16× | — | ||
| Q4 24 | 0.12× | — | ||
| Q3 24 | 6.22× | — | ||
| Q2 24 | 33.57× | — | ||
| Q1 24 | 40.20× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APEI
| American Public Education Inc Segment | $71.0M | 45% |
| Rasmussen University Segment | $66.6M | 42% |
| Hondros College Of Nursing Segment | $20.7M | 13% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
